JP2016520617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520617A5 JP2016520617A5 JP2016517041A JP2016517041A JP2016520617A5 JP 2016520617 A5 JP2016520617 A5 JP 2016520617A5 JP 2016517041 A JP2016517041 A JP 2016517041A JP 2016517041 A JP2016517041 A JP 2016517041A JP 2016520617 A5 JP2016520617 A5 JP 2016520617A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- protecting group
- heterocyclyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000004452 carbocyclyl group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 claims 1
- 102100028646 Nociceptin receptor Human genes 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- JTFAUCXUARBLSG-UHFFFAOYSA-N Cc(c(NC(c1cccc(F)c1)=O)c1)ccc1Oc(cc1)n[n]2c1nc(NC(CC1COC1)=O)c2 Chemical compound Cc(c(NC(c1cccc(F)c1)=O)c1)ccc1Oc(cc1)n[n]2c1nc(NC(CC1COC1)=O)c2 JTFAUCXUARBLSG-UHFFFAOYSA-N 0.000 description 1
- HARQKYGUGVMFLA-UHFFFAOYSA-N Cc1n[n](C)c(C(Nc2c(C)ccc(Oc(cc3)n[n]4c3nc(NC(CCCN3CCC5(COC5)CC3)=O)c4)c2)=O)c1 Chemical compound Cc1n[n](C)c(C(Nc2c(C)ccc(Oc(cc3)n[n]4c3nc(NC(CCCN3CCC5(COC5)CC3)=O)c4)c2)=O)c1 HARQKYGUGVMFLA-UHFFFAOYSA-N 0.000 description 1
- LZBPXQAOGWZIAI-LJQANCHMSA-N Cc1n[n](C)c(C(Nc2cc(Oc(cc3)n[n]4c3nc(NC(CN(CC3)C[C@@H]3N(C)C)=O)c4)ccc2C)=O)c1 Chemical compound Cc1n[n](C)c(C(Nc2cc(Oc(cc3)n[n]4c3nc(NC(CN(CC3)C[C@@H]3N(C)C)=O)c4)ccc2C)=O)c1 LZBPXQAOGWZIAI-LJQANCHMSA-N 0.000 description 1
- CDEIRCCLHGHLDU-UHFFFAOYSA-N Cc1n[n](C)c(C(Nc2cc(Oc(cc3)n[n]4c3nc(NC(NC3COC3)=O)c4)ccc2C)=O)c1 Chemical compound Cc1n[n](C)c(C(Nc2cc(Oc(cc3)n[n]4c3nc(NC(NC3COC3)=O)c4)ccc2C)=O)c1 CDEIRCCLHGHLDU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829117P | 2013-05-30 | 2013-05-30 | |
| US61/829,117 | 2013-05-30 | ||
| US201361898719P | 2013-11-01 | 2013-11-01 | |
| US61/898,719 | 2013-11-01 | ||
| PCT/US2014/040231 WO2014197313A2 (en) | 2013-05-30 | 2014-05-30 | Novel compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520617A JP2016520617A (ja) | 2016-07-14 |
| JP2016520617A5 true JP2016520617A5 (enExample) | 2017-07-20 |
| JP6557654B2 JP6557654B2 (ja) | 2019-08-07 |
Family
ID=52008726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517041A Expired - Fee Related JP6557654B2 (ja) | 2013-05-30 | 2014-05-30 | 新規の化合物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9988386B2 (enExample) |
| EP (1) | EP3003314B1 (enExample) |
| JP (1) | JP6557654B2 (enExample) |
| AU (1) | AU2014275198B2 (enExample) |
| CA (1) | CA2913417A1 (enExample) |
| HK (1) | HK1223307A1 (enExample) |
| WO (1) | WO2014197313A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2913417A1 (en) * | 2013-05-30 | 2014-12-11 | Kala Pharmaceuticals, Inc. | Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor |
| KR102563675B1 (ko) * | 2014-09-30 | 2023-08-04 | 트랜지션즈 옵티칼 인코포레이티드 | 자외선 광 흡수제 |
| WO2016086026A1 (en) * | 2014-11-26 | 2016-06-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1341771A2 (en) * | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| KR20090047509A (ko) | 2006-08-04 | 2009-05-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 헤테로시클릭 유도체 및 이의 용도 |
| JPWO2008016131A1 (ja) * | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| EP2184285B1 (en) * | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2009096435A1 (ja) * | 2008-01-29 | 2009-08-06 | Takeda Pharmaceutical Company Limited | 縮合複素環誘導体およびその用途 |
| WO2010032880A2 (en) | 2008-09-19 | 2010-03-25 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| JP2010126530A (ja) * | 2008-12-01 | 2010-06-10 | Takeda Chem Ind Ltd | 縮合複素環誘導体およびその用途 |
| NZ741873A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| CA2913417A1 (en) * | 2013-05-30 | 2014-12-11 | Kala Pharmaceuticals, Inc. | Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor |
-
2014
- 2014-05-30 CA CA2913417A patent/CA2913417A1/en not_active Abandoned
- 2014-05-30 JP JP2016517041A patent/JP6557654B2/ja not_active Expired - Fee Related
- 2014-05-30 WO PCT/US2014/040231 patent/WO2014197313A2/en not_active Ceased
- 2014-05-30 EP EP14807232.5A patent/EP3003314B1/en not_active Not-in-force
- 2014-05-30 HK HK16111737.7A patent/HK1223307A1/zh unknown
- 2014-05-30 US US14/894,214 patent/US9988386B2/en active Active
- 2014-05-30 AU AU2014275198A patent/AU2014275198B2/en not_active Ceased
-
2018
- 2018-05-03 US US15/970,740 patent/US10351570B2/en active Active
- 2018-06-21 US US16/014,937 patent/US10544151B2/en active Active
-
2019
- 2019-05-24 US US16/422,606 patent/US10954244B2/en not_active Expired - Fee Related
-
2021
- 2021-02-02 US US17/165,791 patent/US20210380588A1/en not_active Abandoned